Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.09, FiscalAI reports. Sonoma Pharmaceuticals had a negative net margin of 10.33% and a negative return on equity of 21.41%. The business had revenue of $7.17 million during the quarter, compared to analyst estimates of $5.29 million.
Sonoma Pharmaceuticals Trading Up 0.9%
NASDAQ:SNOA traded up $0.01 during trading hours on Tuesday, hitting $1.14. 89,800 shares of the company were exchanged, compared to its average volume of 113,565. The stock has a market capitalization of $5.46 million, a price-to-earnings ratio of -0.93 and a beta of 1.31. Sonoma Pharmaceuticals has a one year low of $0.85 and a one year high of $3.95. The company has a fifty day simple moving average of $1.21 and a 200 day simple moving average of $1.66.
Wall Street Analysts Forecast Growth
Separately, Weiss Ratings lowered shares of Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. One investment analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company has an average rating of “Sell”.
Read Our Latest Report on Sonoma Pharmaceuticals
Sonoma Pharmaceuticals Company Profile
Sonoma Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing and commercializing non-antibiotic and non-steroidal products for human and animal health. Its products are designed for applications including dermatology, wound care, eye care and veterinary treatment. The company’s product portfolio is based primarily on Microcyn technology, a stabilized hypochlorous acid solution intended to cleanse, debride and manage wounds and various skin conditions. Products marketed under the company’s brands have included Dermacyn, for wound and skin care, and Ocucyn, for ophthalmic care, along with veterinary products and other prescription and over-the-counter formulations.
Further Reading
- Five stocks we like better than Sonoma Pharmaceuticals
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
